Enoch Kariuki Buys Shares in Zentalis Pharmaceuticals

On June 16, 2026, Enoch Kariuki bought 57,100 shares of Zentalis Pharmaceuticals, Inc. (NasdaqGM: ZNTL). The purchase did not have a disclosed transaction value, but it adds to the insider's stake in the company. Shares of Zentalis were trading around $3.70 at the time of the transaction.

Insider Buying and Selling at Zentalis Pharmaceuticals, Inc.

On the same day as Kariuki's purchase, several other insiders, including Jan Skvarka, David Michael Johnson, Luke Nathaniel Walker, and Scott Dunseth Myers, each acquired 57,100 shares. Additionally, Shannon Campbell bought 114,200 shares on May 26, 2026. None of these transactions were part of a pre-planned trading program.

Other Institutional Activity in Zentalis Pharmaceuticals

Two Sigma Investments, LP increased its position in Zentalis by 1,485,112 shares, ending with 2,956,526 shares valued at about $6.92 million. Meanwhile, Squadron Capital Management LLC added 3,631,000 shares, bringing its total to 3,631,000 shares worth approximately $8.50 million. Conversely, Renaissance Technologies LLC reduced its holdings by 945,600 shares, leaving it with 1,938,145 shares valued at $4.54 million.

Zentalis Pharmaceuticals Stock Snapshot

Zentalis Pharmaceuticals has a market capitalization of approximately $263.4 million. The company's stock has experienced a 52-week low of $1.13 and a high of $6.95. It has a 50-day moving average of $4.11 and a 200-day moving average of $2.50. The company's forward price-to-earnings ratio is not meaningful due to its lack of profitability, and it has a beta of 1.976.

Analysts Set New Price Targets

On April 10, 2026, Guggenheim maintained its 'buy' rating on Zentalis Pharmaceuticals with a price target of $10. The firm had reiterated a 'buy' rating with a $6 target in March. Overall, the consensus among eight analysts is a 'buy' rating, with a mean price target of $6.50.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc. is a biopharmaceutical company based in San Diego, California, focusing on developing small molecule therapeutics for cancer treatment. The company is advancing azenosertib, which is in Phase 3 trials for ovarian cancer, and other candidates for various tumor types. Led by CEO Ms. Julie M. Eastland, the company employs 106 people and collaborates with Recurium IP Holdings, LLC.

Bottom Line

Enoch Kariuki's recent purchase of Zentalis Pharmaceuticals shares adds to the company's insider ownership, reflecting potential confidence in its future. Investors keep an eye on such insider activities for insights, though these transactions do not necessarily predict stock performance. With ongoing clinical trials and analyst interest, Zentalis remains a company to watch in the biotech sector.